BMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.

ABSTRACT:

SUBMITTER: Xu G 

PROVIDER: S-EPMC9574487 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature